We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Ex vivo depotentiation of conditioning-induced potentiation at thalamic input synapses onto the lateral amygdala requires GluN2B-containing NMDA receptors.
Neuroscience Letters 2012 November 22
We have previously characterized the ex vivo depotentiation (depotentiation(ex vivo)) of conditioning-induced synaptic potentiation at thalamic input synapses onto the lateral amygdala (T-LA synapses) as a potential cellular substrate for fear extinction: both depotentiation(ex vivo) and fear extinction require NMDA receptors, mitogen-activated protein kinases, metabotropic glutamate receptor 1, de novo protein synthesis and AMPA receptor internalization in the amygdala. Surprisingly, as shown in our and other previous studies, ifenprodil, an antagonist of GluN2B-containing NMDA receptors, fails to inhibit depotentiation(ex vivo) at a saturating concentration (10μM), although it has been suggested that GluN2B-containing NMDA receptors are required for fear extinction. Because ifenprodil is also known to act on other molecular targets in addition to GluN2B-containing NMDA receptors, especially at high concentrations (i.e., ≥10μM), the ineffectiveness of 10μM of ifenprodil may be due to its side effects. Therefore, in the present study, we tested Ro25-6981, a more specific antagonist of GluN2B-containing NMDA receptors, and a lower concentration (3μM) of ifenprodil, which may reduce any possible side effects. Ro25-6981 (3μM) blocked both depotentiation(ex vivo) and late-phase long-term potentiation at T-LA synapses. While 10μM ifenprodil failed to inhibit depotentiation(ex vivo), a lower concentration (3μM) of ifenprodil blocked depotentiation(ex vivo). Together, our findings suggest that depotentiation(ex vivo) requires GluN2B-containing NMDA receptors.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app